Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.21.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Product sales $ 0 $ 18
Operating cost and expense    
Cost of product sales 1,610 1,454
Research and development cost 289 242
General and administrative expense 2,299 2,385
Total operating expense 4,198 4,081
Loss from operations (4,198) (4,063)
Other income and (expense)    
Insurance proceeds net of related expenses (12) (203)
PPP loan forgiveness 131 0
Interest expense (5) (183)
Interest and other income 0 22
Total income (expense), net 114 (364)
Loss before income tax expense (4,084) (4,427)
Income tax expense (2) 0
Net loss $ (4,086) $ (4,427)
Weighted average shares outstanding, basic and diluted (in shares) 66,877,948 59,582,603
Basic and diluted net loss per share (in dollars per share) $ (0.06) $ (0.07)